AU2003262926A1 - Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders - Google Patents

Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Info

Publication number
AU2003262926A1
AU2003262926A1 AU2003262926A AU2003262926A AU2003262926A1 AU 2003262926 A1 AU2003262926 A1 AU 2003262926A1 AU 2003262926 A AU2003262926 A AU 2003262926A AU 2003262926 A AU2003262926 A AU 2003262926A AU 2003262926 A1 AU2003262926 A1 AU 2003262926A1
Authority
AU
Australia
Prior art keywords
sub
obesity
receptor antagonists
selective
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003262926A
Other languages
English (en)
Inventor
Duane A. Burnett
William J. Greenlee
Thavalakulam K. Sasikumar
Wen-Lian Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2003262926A1 publication Critical patent/AU2003262926A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003262926A 2002-08-29 2003-08-27 Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders Abandoned AU2003262926A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40685602P 2002-08-29 2002-08-29
US60/406,856 2002-08-29
PCT/US2003/026878 WO2004020442A1 (en) 2002-08-29 2003-08-27 Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Publications (1)

Publication Number Publication Date
AU2003262926A1 true AU2003262926A1 (en) 2004-03-19

Family

ID=31978370

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003262926A Abandoned AU2003262926A1 (en) 2002-08-29 2003-08-27 Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Country Status (11)

Country Link
US (1) US7211574B2 (enExample)
EP (1) EP1537115B1 (enExample)
JP (1) JP4555685B2 (enExample)
CN (1) CN1688584A (enExample)
AT (1) ATE396996T1 (enExample)
AU (1) AU2003262926A1 (enExample)
CA (1) CA2495879C (enExample)
DE (1) DE60321354D1 (enExample)
ES (1) ES2308016T3 (enExample)
MX (1) MXPA05002249A (enExample)
WO (1) WO2004020442A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1823059A (zh) * 2003-05-22 2006-08-23 先灵公司 作为治疗肥胖和CNS疾病的选择性D<sub>1</sub>/D<sub>5</sub>受体拮抗剂的5－H－苯并[D]萘并[2,1－B]氮杂䓬衍生物
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
WO1987004430A2 (en) * 1986-01-16 1987-07-30 Schering Corporation Fused benzazepines
ATE78467T1 (de) * 1987-07-15 1992-08-15 Schering Corp Kondensierte benzazepine.
DK325188D0 (da) * 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
WO2003006466A1 (en) * 2001-07-13 2003-01-23 Pharmacia & Upjohn Company Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands

Also Published As

Publication number Publication date
JP4555685B2 (ja) 2010-10-06
CA2495879C (en) 2011-04-26
JP2006501244A (ja) 2006-01-12
CN1688584A (zh) 2005-10-26
DE60321354D1 (de) 2008-07-10
CA2495879A1 (en) 2004-03-11
US7211574B2 (en) 2007-05-01
US20040058906A1 (en) 2004-03-25
WO2004020442A1 (en) 2004-03-11
ES2308016T3 (es) 2008-12-01
MXPA05002249A (es) 2005-06-08
EP1537115A1 (en) 2005-06-08
EP1537115B1 (en) 2008-05-28
ATE396996T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
WO2003045918A8 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2003028641A3 (en) Mch receptor antagonists
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
GEP20074197B (en) 5ht2c receptor modulators
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
WO2004005262A8 (en) New neuropeptide y y5 receptor antagonists
GB0504828D0 (en) Therapeutic agents
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
MXPA05013711A (es) Derivados 3-sustituidos de 5,6-diaril-pirazin-2-carboxi-amida y -2-sulfonamida, como moduladores de cb1.
WO2006014618A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
MXPA06003363A (es) Derivados de fenil-piperazina como moduladores de receptores muscarinicos.
WO2004016256A3 (en) AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
WO2006044293A3 (en) Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
WO2005000231A3 (en) Il-8 receptor antagonists
WO2004110385A3 (en) Modulators of the glucocorticoid receptor and method
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
NZ514696A (en) IL-8 receptor antagonists
MXPA05009193A (es) Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
WO2005035504A3 (en) 5-h -benzo [d] naphth [2, 1-b] azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase